HEALING AND RECOVERY
KPV
Also known as Lys-Pro-Val, α-MSH C-terminal tripeptide, alpha-MSH 11-13
KPV is a research peptide with no completed human clinical trials. Preclinical rodent data show anti-inflammatory effects relevant to inflammatory bowel disease, skin inflammation, and other inflammatory conditions. No human safety or efficacy data are available.
Reference dose range
100–500 mcg
Reported frequency
Once or twice daily in research references
Reported routes
Subcutaneous, Oral, Topical
Very short plasma half-life, on the order of minutes. Oral bioavailability has been described in animal models, attributed to resistance to intestinal peptidases.
Use the calculators for arithmetic only
Mechanism
KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains anti-inflammatory activity through melanocortin signalling (MC1R and MC3R) without the melanogenic effects of the full peptide, and suppresses pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta along with NF-kB signalling. Oral activity has been shown in murine models of inflammatory bowel disease.
Reported effects
Anti-inflammatory effects in models of inflammatory bowel disease (animal studies)
Suppression of pro-inflammatory cytokines (in vitro and animal evidence)
Potential tissue-repair properties (preclinical)
Oral bioavailability demonstrated (animal studies)
Commonly reported side effects
No human safety data available
Administration-site reactions, via the injectable route
Theoretical risk of immune modulation
Certainty and limits
The evidence is entirely preclinical. There are no human trials, and the reported benefits rest on in vitro and animal-model data. The mechanism is biologically plausible, but translation to human clinical benefit is unproven.
This is part of the reviewed public subset. The signed-in app includes a broader peptide reference library alongside private tracking tools.